Founded in 2015, Oricell Therapeutics is dedicated to pioneering innovative and clinically valuable immunotherapies focusing on a wide range of indications. Committed to cost-effective and enduring cellular drugs, we strive to address global clinical needs, aiming to profoundly impact patients' lives and help them "return to health, restart vitality" through our advancements in life sciences.
Dedicated to developing effective and accessible immunotherapeutics
and extend the life of cancer patients.
Dedicated to developing effective
and accessible immunotherapeutics
and extend the life of cancer patients.
To become a global leader in innovation-drive
novel immunotherapies.
Patient-first, Scientific Excellence,
Integrity, Synergy and Collaboration
Helen is a successful business leader with 3 decades of operations and management experience. She has a remarkable track record, having served as a C-suite manager for two publicly listed companies and one private company across various industries.
Helen received her EMBA at CEIBS and Ph.D. at Tongji University in China.
Peter is a highly accomplished molecular biologist and immunologist, boasting over 20 years of extensive expertise in the field. He remains unwavering in his dedication to advancing the scientific domain through pioneering research in cell development and metabolism, with a specific emphasis on tumor immune microenvironment. Notably, he prioritizes innovation and has effectively guided his team in creating a cutting-edge technology platform for Oricell.
Peter completed his post-doctoral training at University of Medicine and Dentistry of New Jersey.
Dr. Guo brings over 20 years of experience in biopharmaceutical R&D and management, with deep expertise in oncology strategy, clinical development, and regulatory registration. He most recently served as Executive Director, Group CEO, and Chairman of Genor Biotech, where he led the pivotal registration study and NDA for the breast cancer therapy GB491, advanced multiple bispecific and trispecific antibody programs, and spearheaded an asset-light operating model with several international collaborations. Previously, he held senior leadership roles at multinational pharmaceutical companies, including Head and Vice President of the Merck China R&D Center and Head of the Pfizer Wuhan R&D Center and Clinical Pharmacology for Asia, contributing to the clinical development and registration of multiple new drugs. Dr. Guo holds a Ph.D. in Clinical Pharmacology from the University of Toronto.
With over 30 years of experience in the pharmaceutical industry, Dr. Rick Xu has respectively worked for Sterling Winthrop, Pfizer, Hoffman-La Roche and Genentech, and successfully designed, engineered and developed two multi-billion dollar products, the PEGSYS and the Long Acting Filgrastim. Since 2006, Dr. Xu has been acting as Sr. Director, Expert Scientist of Translational Medicine in Oncology and Clinical Pharmacology, focusing on global clinical drug development of immune oncology therapeutic products. Dr. Xu has served as the president and chairman of SAPA and member of China RDA Drug Clinical Trials Committee.
Iris is an ex-life science investment banker with over 11 years’ experiences in Asia and the U.S. Prior to joining Oricell, Iris served as Executive Director at J.P. Morgan’s global investment banking team and Vice President at Bank of America Merrill Lynch, where her major role was to advise, strategize and execute corporate finance and capital market transactions for leading pharma companies across regions. Iris received her bachelor degree in BBA of Finance and BS of Psychology from Emory University and MSc in Law and Accounting from LSE.
Dr. Kumar is the Mark and Judy Mullins Professor of Hematologic Malignancies at Mayo Clinic as well as Research Chair, Division of Hematology, Department of Internal Medicine at Mayo. He received his medical degree from All-India Institute of Medical Sciences and completed his residency and fellowship training in internal medicine, medical oncology, and hematology at Mayo and Dana-Farber Harvard Cancer Institute. He is also an active member and leader of various professional societies and committees, such as the American Society of Hematology, the International Myeloma Society, the International Society of Amyloidosis, and the National Comprehensive Cancer Network.
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute.
Ori-C101 receives NMPA approval for Phase II clinical trial
Closed $113M pre-IPO financing.
Ori‑C101: Phase I clinical data selected for an oral presentation at ASCO 2026.
OriV508: Preclinical data featured in a poster at ASCO 2026.
OriC902: Preclinical data published/presented at ESLA 2026.
Named a Top‑10 enterprise in the Advanced Therapy track at the 4th ZY Star Awards.
Ranked Top‑3 in “Innovative Pharma & Biologics” in the 2026 VB Future Healthcare 100 by VB Data
Ori‑C101: Phase I Clinical and dual‑target CAR‑T preclinical data selected for poster presentation at ASCO 2025.
OriCAR‑017: Received FDA IND clearance.
OriC613: Received NMPA IND approval.
BCMA×GPRC5D bispecific CAR‑T: Preclinical data presented at AACR 2025.
Invited to deliver an oral presentation at the 43rd J.P. Morgan Healthcare Conference.
OriCAR‑017: Long‑term follow‑up data selected for an oral presentation at ASCO 2024.
OriCAR‑017: Received FDA Fast Track designation.
OriC613: Obtained NMPA IND approval.
OriC322: Preclinical data selected for an oral presentation at STIC 2024 and poster presentation at ASH 2024.
Prof. Ken Anderson and Prof. Shaji Kumar joined the Scientific Advisory Board.
Established in‑house OnGo Rapid Process CMC Platform, significantly reducing production cycle time and cost.
Established in‑house lentiviral vector (LVV) development platform with high titer, yield, and scalability.
Invited to deliver an oral presentation at the 42nd J.P. Morgan Healthcare Conference.
Closed $45M Series B1 financing.
Ori C101: Dosed the first patient in the Phase I trial.
OriCAR 017: Long term follow up data from the IIT accepted for publication in The Lancet Haematology.
OriCAR 017: Completed China–US technology transfer within six months and submitted an IND to the FDA.
Preclinical data for four programs (including OriCAR‑017) accepted for poster presentation at SITC 2023.
Named one of the Top‑10 Most Notable Cell Therapy Companies globally.
Listed among 2023 China Potential Unicorn Enterprises.
Awarded “Future Star – Top 100 Rising Companies” by China Entrepreneur Magazine.
Won the Gold Award at the Shanghai Haiju Talents Global Innovation & Entrepreneurship Competition.
Reports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
OriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress
CAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022
GPRC5D CAR-T receives Orphan Drug Designation from FDA
Receives Implied License from NMPA for Ori-C101 IND Application
Raises Over $120 Million in Series B Financing
Officially renamed "OriCell Therapeutics (Shanghai) Co., Ltd."
The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
Oricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
Oricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List
Reached a global License-out agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD
Received the A round of financing of 200 million CNY, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Gaosen Assets
Established the Shanghai Academician (Expert) Workstation
Established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
Won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
December Received the pre-A round of exclusive funding from Qiming Venture Partners
Research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell
Signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.
Attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields
Proprietary, unique, adaptive CAR-T platform
Focusing on developing first-in-class and best-in-class immunotherapies
More than 10 CAR-T product pipelines
4 in clinical validation stage with 2 in registered phase I clinical trial
Helen is a successful business leader with 3 decades of operations and management experience. She has a remarkable track record, having served as a C-suite manager for two publicly listed companies and one private company across various industries. Additionally, Helen co-founded and successfully led the IPO of Canature (300272).
Helen received her Bachelor degree at Beijing Institute of Technology, EMBA at CEIBS and is a Ph.D. candidate at Tongji University in China.
Peter is a highly accomplished molecular biologist and immunologist, boasting over 20 years of extensive expertise in the field. He remains unwavering in his dedication to advancing the scientific domain through pioneering research in cell development and metabolism, with a specific emphasis on tumor immune microenvironment. Notably, he prioritizes innovation and has effectively guided his team in creating a cutting-edge technology platform for Oricell.
Peter received a doctoral degree in molecular biology and genetics at Second Military Medical University in China and completed his post-doctoral training at University of Medicine and Dentistry of New Jersey.
Dr. Cui brings over 25 years of CMC experience. Prior to joining Oricell, Dr. Cui served as the CTO of Fosun Kite, led the tech transfer, NDA submission and commercial launch of the first autologus CAR-T therapy Yescarta® (Axi-Cel) in China. Before Fosun Kite, Dr. Cui also served in various senior management and scientific roles in MedImmune and AstraZeneca.
Dr. Cui received his Ph.D. at SUNY ESF Syracuse University and completed his post-doctoral training at UCSF.
沪公网安备 31011502019994号